Healthcare resource utilisation and economic burden of patients with adequate and inadequate responses to biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis in Japan.

Ikeda, Kei; Kaneko, Yuko; Tsujita, Yuki; Kawaguchi, Isao; Patel, Jayeshkumar; Yamazaki, Toru; Fang, Siran; Kawahito, Yutaka

Ikeda, Kei; Kaneko, Yuko; Tsujita, Yuki; Kawaguchi, Isao; Patel, Jayeshkumar; Yamazaki, Toru; Fang, Siran; Kawahito, Yutaka.

Afiliação

Ikeda K; Department of Rheumatology, Dokkyo Medical University, Tochigi, Japan.
Kaneko Y; Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tsujita Y; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Kawaguchi I; AbbVie GK, Tokyo, Japan.
Patel J; AbbVie GK, Tokyo, Japan.
Yamazaki T; AbbVie Inc., North Chicago, Illinois, USA.
Fang S; AbbVie GK, Tokyo, Japan.
Kawahito Y; AbbVie Inc., North Chicago, Illinois, USA.

Mod Rheumatol ; 2023 Nov 09.

Article em En | MEDLINE | ID: mdl-37949632

Palavras-chave

Disease-modifying antirheumatic drugs; economic burden; healthcare resource utilisation; responder; rheumatoid arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mod Rheumatol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google